CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
|
|
- Scot Newman
- 5 years ago
- Views:
Transcription
1 CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JUNE 8, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has nothing to disclose in relation to this activity: John I. McNeil, MD 1
2 Howard University CME Accreditation Sponsor Accreditation: Howard University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credits for Physicians: Howard University College of Medicine, Office of Continuing Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category I Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Goulda A. Downer, PHD, RD, LN, CNS Principal Investigator/Project Director CME Disclosures: Planning Committee And Speaker AETC-Capitol Region Telehealth Project Planning Committee: The following committee members have nothing to disclose in relation to this activity: Goulda A. Downer, PhD, RD, LN, CNS John I. McNeil, MD Jean Davis, PHD,DC, PA, MSCR Denise Bailey, MED Speaker: The following speaker has nothing to disclose in relation to this activity: John I. McNeil, MD 2
3 Howard University CME Accreditation Requirements For Internet Viewers Intended Audience: Health service providers: Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Dentists, Nurses, Social Workers, Case Managers and other Clinical Personnel. Webinar Requirements: A computer, phone, etc., with internet accessibility and a telephone line. ØYour presence on the call must be acknowledged at the start of each session. Please log in for the session announce your name loud and clear at the beginning of the session. ØYou will not be able to receive CME credits if you leave the session early. ØAt the end of the Webinar our Training Coordinator will a CME Evaluation Survey. ØAll participants are required to complete and return the CME Evaluation Survey at the end of each session. It may be scanned and ed back to den_bailey@howard.edu, or faxed to: AETC-Capitol Region Telehealth Project (FAX#: ) ATTN: Project Coordinator. Please indicate in your or FAX if you would like to receive CMEs. TEST YOUR KNOWLEDGE 6 3
4 TestYour Knowledge Question #1 HIV Accelerates HCV related Fibrosis: A.True B. False TestYour Knowledge Question #2 The following factors are associated with HIV/HCV Fibrosis Progression: A. Alcohol Consumption B. Male Gender C. Age D. Multiple Transfusions 4
5 TestYour Knowledge Question #3 HCV antibody test means the person is still infectious: A. True B. False TestYour Knowledge Question #4 Which of the following is true about Hepatitis C? A. Cure protects for a life time B. Cannot be treated while treating HIV C. Cannot be treated in someone with cirrhosis D. Can be cured in as little as 8 weeks 5
6 CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS LEARNING OBJECTIVES 1. Describe the epidemiology of HCV 2. Describe progression of liver disease in the setting of HIV/hepatitis C virus (HCV) coinfection 3. Identify currently available antiviral regimens 4. Describe barriers to treatment, including drug-drug interactions 6
7 EPIDEMIOLOGY Ø Five major types, maybe six minor types Ø Estimated 3.5 million people in the US have chronic HCV Ø Yearly, 17,000 get infected Ø Long-term incubation can eventually result in liver failure, liver cancer Ø Every year approximately 12, 000 die from HCV related liver disease WHERE DOES IT COME FROM? ØIt is typically spread when blood from a person infected with the hepatitis C virus enters the blood stream of a non-infected person. ØYes, and sex Ø Transfusions (before 1982) 7
8 RISK FACTORS FOR ACQUIRING HCV SYMPTOMS Ø Silent for years Ø Signs of eventual liver damage o Fever o Fatigue o Jaundice o Dark urine o Grey colored stools o Joint pain 8
9 HIV/HCV COINFECTION Ø Compared to HCV monoinfection o Higher rates of susceptibility to mucosal transmission o Higher rates of persistence o Faster rates of fibrosis o Higher rate of cirrhosis o Increased liver related mortality CARE CASCADE IN HCV 9
10 PROGRESSION OF FIBROSIS IN HCV IMPACT OF HIV COINFECTION 10
11 HIV ACCELERATES HCV RELATED FIBROSIS Kim and Chung Gastroenterology 2009 FACTORS ASSOCIATED WITH HIV/HCV FIBROSIS PROGRESSION ØCD4 count less than 200 cells/mm 3 Ø Alcohol consumption ØOlder age at time of HCV acquisition Di Martino et al Hepatology
12 MODIFIABLE RISK FACTORS FOR DISEASE PROGRESSION Diabetes/ insulin resistance Coinfection with HBV Marijuana HCV THERAPY
13 IMPACT OF HCV CURE CURRENTLY AVAILABLE HCV MEDICATIONS Sofosbuvir/ Ledipasvir Paritaprevir/r Ombitasvir Dasabuvir Daclatasvir/ Sofosbuvir Elbasvir/ grazoprevir Sofosbuvir/ Simeprevir DAA Class Protease Inhibitor X X X NS5A inhibitor X X X X Nucleoside Polymerase Inhibitor X X X Non-Nucleoside Polymerase Inhibitor X Ribavirin X 13
14 THERAPY IN HIV/HCV COINFECTION Ø When compared to HCV monoinfection: o Duration of treatment usually the same o Medication regimens often the same o Adverse events the same (almost none) o OUTCOMES the same o But. Ø Drug-drug interactions may be significant POOR HISTORICAL RESPONSE IN HIV/HCV Poordad F et al, NEJM 2011; 364: vs. Sulkowski et al. Lancet Infect Dis 2013; 13(7): Jacobson I et al, NEJM 2011; 364: vs. Sulkowski et al. Ann Intern Med 2013; 159(2): Antiviral Drugs Advisory Committee Meeting, FDA review, 10/24/13 C208, C216, C206, C212, HPC3007, Dieterich et al. Clin Infect Disease 2014 (epub ahead of print) Lawitz et al. NEJM 2013 versus Torres-Rodriguez et al., IDSA 2013 Osinusi et al., JAMA 2013;310(8): versus Sulkowski et al. JAMA 2014;312(4):
15 EQUIVALENT HIV/HCV RESPONSE TO DAAS Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373: Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370: Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373: Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370: Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir codosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313: Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370: Dieterich D, Rockstroh JK, Orkin C, et al. 7. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomized, open-label trial. Lancet HIV. 2015;2:e Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163:1-13. ION 4: SOFOSBUVIR/ LEDIPASVIR IN HIV/HCV COINFECTION Naggie et al NEJM
16 ION 4: SOFOSBUVIR/ LEDIPASVIR IN HIV/HCV COINFECTION Naggie et al NEJM ION 4: SOFOSBUVIR/ LEDIPASVIR IN HIV/HCV COINFECTION Naggie et al NEJM
17 TAKE HOME: SOFOSBUVIR/LEDIPASVIR ØHCV Genotypes 1, 4 ØSingle pill daily usually 12 weeks Ø Effective in treatment naïve, experienced, cirrhotic, non cirrhotic Ø Some Drug-Drug interactions C-EDGE COINFECTION: ELBASVIR/GRAZOPREVIR IN HIV/HCV COINFECTION Rockstroh et al Lancet HIV
18 C-EDGE COINFECTION ELBASVIR/GRAZOPREVIR IN HIV/HCV COINFECTION Rockstroh et al Lancet HIV ELBASVIR/GRAZOPREVIR EFFECT OF BASELINE RAVS Zeuzem et al Ann Int Med
19 ELBASVIR/GRAZOPREVIR BASELINE NS5A RAVS Zeuzem et al Ann Int Med ELBASVIR/ GRAZOPREVIR IN RENAL DISEASE Roth et al Lancet
20 TAKE HOME: GRAZOPREVIR ELBASVIR Ø Genotype 1 and 4 Ø Single pill daily Ø Effective in treatment naïve, experienced, cirrhotic, non cirrhotic Ø Some Drug-Drug Interactions Ø Need to check baseline RAVs in 1a Ø Useful in Renal disease, including ESRD o No dose adjustment Ø Cost? ALLY -2 DACLATASVIR/ SOFOSBUVIR GENOTYPE IN HIV/HCV COINFECTION Wyles et al NEJM
21 ALLY-2 DACLATASVIR/SOFOSBUVIR GENOTYPE 1 HIV/HCV COINFECTION Wyles et al NEJM COMPARISON OF ART ALLOWED IN PHASE 3 CLINICAL TRIALS 21
22 TAKE HOME: DACLATASVIR/ SOFOSBUVIR ØGenotypes 1 through 4 Ø2 pills a day Ø Some Drug-Drug interactions but can adjust dose of DCV ØMay be expensive o 2 separate manufacturers DRUG-DRUG INTERACTIONS Simeprevir Sofosbuvir Ledipasvir Daclatasvir Paritaprevir, ritonavir, ombitasvir plus dasabuvir (PrOD) Paritaprevir, ritonavir, ombitasvir (PrO) Grazoprevir/ Elbasvir Ritonavir-boosted atazanavir Ritonavir- boosted darunavir Ritonavir-boosted lopinavir Ritonavir-boosted tipranavir No data No data Ledipasvir ; atazanavir a (okay with TAF not TDF) Simeprevir ; darunavir Efavirenz Simeprevir ; efavirenz Rilpivirine Simeprevir ; rilpivirine Sofosbuvir ; darunavir Ledipasvir, darunavir a (okay with TAF not TDF) Daclatasvir b Paritaprevir ; atazanavir Daclatasvir ; darunavir Paritaprevir /; darunavir No data No data No data a Daclatasvir ; lopinavir Paritaprevir ; lopinavir Paritaprevir ; atazanavir Paritaprevir ; darunavir Paritaprevir ; lopinavir Grazoprevir ; elbasvir ; atazanavir Grazoprevir ; elbasvir ; darunavir Grazoprevir ; elbasvir ; lopinavir No data No data No data No data No data No data No data Sofosbuvir ; efavirenz Sofosbuvir ; rilpivirine efavirenz a elbasvir ; Ledipasvir ; Daclatasvir b No pharmacokinetic data c No data Grazoprevir ; Ledipasvir ; rilpivirine No data Paritaprevir ; rilpivirine efavirenz No data Grazoprevir ; elbasvir ; rilpivirine Etravirine No data No data No data Daclatasvir b No data No data No data Raltegravir Simeprevir ; Sofosbuvir ; Ledipasvir ; No data PrOD ; PrO ; Grazoprevir ; raltegravir raltegravir raltegravir raltegravir raltegravir elbasvir ; raltegravir Cobicistat-boosted elvitegravir No data Cobicistat a ; sofosbuvir (okay with TAF not TDF) Cobicistat ; ledipasvir a (okay with TAF not TDF) Dolutegravir No data No data Ledipasvir ; dolutegravir No data No data No data No data Daclatasvir ; dolutegravir Paritaprevir ; dolutegravir No data Grazoprevir ; elbasvir ; dolutegravir Maraviroc No data No data No data No data No data No data No data Tenofovir disoproxil fumarate Simeprevir ; tenofovir Sofosbuvir ; tenofovir Ledipasvir ; tenofovir Daclatasvir ; tenofovir PrOD ; tenofovir Pro ; tenofovir Grazoprevir ; elbasvir ; tenofovir 22
23 DRUG-DRUG INTERACTIONS KEY POINTS IN TREATING HCV IN HIV/HCV COINFECTION Ø High priority due to faster progression to cirrhosis Ø DAA therapy is highly effective o Drug-Drug Interactions may guide therapy o Cost will guide therapy Ø Many HCV regimens will NOT require alteration in HIV therapy Ø If change in HIV regimen is needed remember: o HCV therapy is short, HIV is very long o Ensure patient is stable on new HIV regimen x three-six months before treating HCV 23
24 WHAT S NEW IN HIV/HCV Wyles et al EASL 2016 ASTRAL 5 VELPATASVIR/ SOFOSBUVIR IN HIV/HCV COINFECTED Wyles et al EASL
25 ASTRAL 5 VELPATASVIR/ SOFOSBUVIR IN HIV/HCV COINFECTED Wyles et al EASL 2016 ACUTE HCV IN HIV INFECTED PATIENTS Rockstroh CROI
26 LEDIPASVIR/ SOFOSBUVIR IN ACUTE HCV IN PATIENTS WITH HIV Rockstroh CROI 2016 TEST YOUR KNOWLEDGE 52 26
27 TestYour Knowledge Question #5 HIV Accelerates HCV related Fibrosis: A.True B. False TestYour Knowledge Question #6 The following factors are associated with HIV/HCV Fibrosis Progression: A. Alcohol Consumption B. Male Gender C. Age D. Multiple Transfusions 27
28 TestYour Knowledge Question #7 HCV antibody test means the person is still infectious: A. True B. False TestYour Knowledge Question #8 Which of the following is true about Hepatitis C? A. Cure protects for a life time B. Cannot be treated while treating HIV C. Cannot be treated in someone with cirrhosis D. Can be cured in as little as 8 weeks 28
29 Howard University HURB th Street NW, 2 nd Floor Washington, DC (Office) (Fax) As a Reminder: At the end of the Webinar, All participants are required to complete and return the CME Evaluation Survey. It may be scanned and ed back to den_bailey@howard.edu, or faxed to: AETC-Capitol Region Telehealth Center (FAX#: ) ATTN: Training Coordinator. Please indicate in your or FAX if you would like to receive CMEs
5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationGUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE
GUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JANUARY 25, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND APRIL 26, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationTreatment of HCV in Persons with HIV Coinfection
Hepatitis C Online PDF created October 2, 2018, 12:45 pm Treatment of HCV in Persons with HIV Coinfection This is a PDF version of the following document: Section 6: Treatment of Key Populations and Unique
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationIsabel Rambob, DDS Assistant Professor University of Maryland School of Dentistry
Isabel Rambob, DDS Assistant Professor University of Maryland School of Dentistry Sponsor Accreditation: Howard University College of Medicine is accredited by the Accreditation Council for Continuing
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationA Practical Approach to HIV/HCV Co-infection
A Practical Approach to HIV/HCV Co-infection Focus on Drug-Drug Interactions Amy Hirsch Shumaker, PharmD, BCPS HIV/Hepatitis C Clinical Pharmacy Specialist Louis Stokes Cleveland VA Medical Center Andrea
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationSTRATEGIES TO REDUCE HIV INFECTION AMONG HBCU COLLEGE STUDENTS
STRATEGIES TO REDUCE HIV INFECTION AMONG HBCU COLLEGE STUDENTS ORLANDO O. HARRIS, PhD, RN, FNP, MPH FELLOW CENTER FOR AIDS PREVENTION STUDIES (CAPS) DEPARTMENT OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationP4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines
P4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines Presenter: Stacey B. Trooskin, M.D., Ph.D Director of Viral Hepatitis Programs Philadelphia FIGHT Community Health Centers
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationHepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS
Hepatitis Mini-Symposium Johns Hopkins Brazil Conference HIV/AIDS April 15, 2016 Ashwin Balagopal, M.D. and Michael Chattergoon, M.D./Ph.D. Division of Infectious Diseases Center for Viral Hepatitis Research
More informationGUIDELINES ON INCORPORATING HIV PREVENTION INTO MEDICAL CARE
GUIDELINES ON INCORPORATING HIV PREVENTION INTO MEDICAL CARE JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JANUARY 26, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationMavyret (glecaprevir/pibrentasvir)
(glecaprevir/pibrentasvir) Override(s) Prior Authorization Quantity Limit Medication (glecaprevir/pibrentasvir) Approval Duration Based on Genotype, Treatment Status, or Cirrhosis Status. Quantity Limit
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationDogma: HCV treatment for eradication. Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015
Dogma: HCV treatment for eradication Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015 Disclosures Some discussion of non-hc approved compounds Industry:
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHCV/HIV Coinfection ANTON AND MARGARET FUISZ CHAIR IN MEDICINE. HIV and HCV Share Risk Factors PREVALENCE OF CO-INFECTION BY RISK FACTOR 60%
HCV/HIV Coinfection BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY HIV and HCV Share Risk Factors PREVALENCE
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
Review Article HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals Donald P. Rice Jr.* 1, John J. Faragon 2, Sarah Banks 3 and Lisa M. Chirch 1 1 Division of Infectious Diseases,
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationBIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP) GUIDELINES
BIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP) GUIDELINES ORLANDO O. HARRIS, PHD, RN, FNP, MPH POST-DOCTORAL FELLOW, CENTER FOR AIDS PREVENTION STUDIES, DEPARTMENT OF MEDICINE
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationHepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Clinical Infectious Diseases IDSA FEATURES Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel a (See
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationWhat is Hepatitis C Virus (HCV)?
HEPATITIS C VIRUS (HCV) What is Hepatitis C Virus (HCV)? Hepatitis is an inflammation (swelling or tenderness) of the liver. Hepatitis C virus (HCV) is the most common form of viral hepatitis and usually
More informationConsiderations for the management of Hepatitis C in patients with HIV co-infection
Considerations for the management of Hepatitis C in patients with HIV co-infection Marcella Honkonen, PharmD, BCPS Sunday, February 22, 2012 at 10:15 AM AzPA Southwest Clinical Conference JW Marriott,
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV- Coinfected Patients at a Large, Urban, Ryan White Clinic Manish
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More information